SGLT2 inhibitors and the diabetic kidney

Diabetes Care

Volumn 39, Issue , 2016, Pages S165-S171

  Fioretto, Paola ^a   Zambon, Alberto ^a   Rossato, Marco ^a   Busetto, Luca ^a   Vettor, Roberto ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE CONTROL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL STUDY; FEEDBACK SYSTEM; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ARTERY; KIDNEY TUBULE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SODIUM ABSORPTION; VASOCONSTRICTION; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GLOMERULUS; GLUCOSE BLOOD LEVEL; KIDNEY; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ALBUMINURIA; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84979582003     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS15-3006     Document Type: Article

References (54)

1. United States Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, 2012
2. Parving H-H, Mauer M, Fioretto P, Rossing P, Ritz E. Diabetic nephropathy. In Brenner & Rector's The Kidney. 9th ed. Brenner BM, Ed. Philadelphia, PA, Saunders Elsevier, 2012, p. 1411-1454
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
5. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572
6. Zoungas S, Chalmers J, Neal B, et al.; ADVANCEON Collaborative Group. Follow-up of bloodpressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371:1392-1406
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329: 1456-1462
8. Lewis EJ, Hunsicker LG, ClarkeWR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
9. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
10. Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol 2010;6:19-25
11. ?Skrtíc M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015;24:96-103
12. Komala MG, Panchapakesan U, Pollock C, Mather A. Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens 2013;22:113-119
13. Freitas HS, Anĥe GF, Melo KF, et al. Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008;149:717-724
14. Rahmoune H, Thompson PW,Ward JM,Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-3434
15. DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36:3169-3176
16. Ferrannini E, Veltkamp SA, Smulders RA, Kadokura T. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 2013;36:1260-1265
17. Gilbert RE. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int 2014;86: 693-700
18. De Nicola L, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis 2014;64:16-24
19. Schernthaner G,Mogensen CE, Schernthaner GH. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res 2014;11:306-323
20. Lovshin JA, Gilbert RE. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective? Curr Hypertens Rep 2015;17:551
21. Kohan DE, Fioretto P, Tang W, List JF. Longterm study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-971
22. Yale JF, Bakris G, Cariou B, et al.; DiA3004 Study Group. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014;16:1016-1027
23. Barnett AH, Mithal A, Manassie J, et al.; EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369-384
24. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983;23:647-655
25. Magee GM, Bilous RW, Cardwell CR, et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009;52:691-697
26. Ruggenenti P, Porrini EL, Gaspari F, et al.; GFR Study Investigators. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012;35:2061-2068
27. Nelson RG, Bennett PH, Beck GJ, et al.; Diabetic Renal Disease Study Group. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 1996;335:1636-1642
28. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 2004;286:F8-F15
29. Thomson SC, Blantz RC. Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis. J Am Soc Nephrol 2008;19:2272-2275
30. Ditzel J, Lervang HH, Brøchner-Mortensen J. Renal sodiummetabolism in relation to hypertension in diabetes. DiabeteMetab 1989;15:292-295
31. Hannedouche TP, Delgado AG, Gnionsahe DA, Boitard C, Lacour B, Grünfeld JP. Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes. Kidney Int 1990;37:1126-1133
32. Faulhaber-Walter R, Chen L, Oppermann M, et al. Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J Am Soc Nephrol 2008;19:722-730
33. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J AmSocNephrol 1999;10:2569-2576
34. Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013;304:F156-F167
35. Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.Am J Physiol Regul Integr Comp Physiol 2012;302:R75-R83
36. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597
37. Skrtíc M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014;57:2599-2602
38. Fioretto P,MauerM.Histopathology ofdiabetic nephropathy. Semin Nephrol 2007;27:195-207
39. Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996;39:1569-1576
40. Tang SC, Lai KN. The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol Dial Transplant 2012;27: 3049-3056
41. Liu Y.Newinsights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010;21:212-222
42. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 2013;8:e54442
43. Malatiali S, Francis I, Barac-Nieto M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008;2008:305403
44. Gangadharan Komala M, Gross S,Mudaliar H, et al. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One 2014;9:e108994
45. Gembardt F, Bartaun C, Jarzebska N, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 2014; 307:F317-F325
46. Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 2014;9:e100777
47. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382: 941-950
48. Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 2016;29:391-400
49. Fioretto P, Stefansson BV, Johnsson EKA, Cain VA, SjostromD. Dapagliflozin reduces albuminuria over 2 years in diabetic patients with renal impairment (Abstract). J Am Soc Nephrol 2015;26:1A
50. U.S. Food and Drug Administration. Canagliflozin: advisory committee meeting [Internet]. Available from http://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/Endocrinologicand MetabolicDrugsAdvisoryCommittee/UCM336236 .pdf. Accessed 18 July 2013
51. Cherney D, von Eynatten M, Lund SS, et al. Sodium glucose cotransporter 2 inhibition with empagliflozin reduces microalbuminuria in patients with type 2 diabetes (Abstract). Diabetologia 2014;57(Suppl. 1):S333
52. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 2117-2128
53. Wanner C, Lachin JM, Fitchett DH, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes and chronic kidney disease. Late-breaking abstract presented American Society of Nephrology Kidney Week 2015, 3-8 November 2015, San Diego, CA
54. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013;166:217-223.e11